BACKGROUND AND METHODS. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial, we compared three regimens of primary systemic therapy for newly diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12 cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first relapse after radiation therapy were eligible. No additional radiation therapy was given. Patients who did not have a complete response or who had a relapse with either MOPP alone or ABVD alone were switched to the opposite regimen. RESULTS. Of 361 eligible patients, 123 received MOPP, 123 received MOPP alternating with ABVD, and 115 received ABVD alone. The patients were stratified according to age, stage, previous radiation, histologic features, and performance status. The overall response rate was 93 percent, with complete responses in 77 percent: 67 percent in the MOPP group, 82 percent in the ABVD group, and 83 percent in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the other two regimens, both of which contained doxorubicin). The rates of failure-free survival at five years were 50 percent for MOPP, 61 percent for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and regimen influenced failure-free survival significantly. Overall survival at five years was 66 percent for MOPP, 73 percent for ABVD, and 75 percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the doxorubicin regimens). MOPP had more severe toxic effects on bone marrow than ABVD and was associated with greater reductions in the prescribed dose. CONCLUSIONS. In this trial, ABVD therapy for 6 to 8 months was as effective as 12 months of MOPP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP.
Source Information
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
This article has been cited by other articles:
Hoskin, P. J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B. W., Smith, P., Qian, W., Patrick, P., Popova, B., Pettitt, A., Cunningham, D., Pettengell, R., Sweetenham, J., Linch, D., Johnson, P. W.M.
(2009). Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. JCO
27: 5390-5396
[Abstract][Full Text]
Fernandez de Larrea, C., Martinez, C., Gaya, A., Lopez-Guillermo, A., Rovira, M., Fernandez-Aviles, F., Lozano, M., Bosch, F., Esteve, J., Nomdedeu, B., Montserrat, E., Carreras, E.
(2009). Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. Ann Oncol
0: mdp487v1-mdp487
[Abstract][Full Text]
Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.-D., Koch, P., Hanel, M., Pfreundschuh, M., Wilhelm, M., Trumper, L., Aulitzky, W.-E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.-K., Hasenclever, D., Loffler, M.
(2009). Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. JCO
27: 4548-4554
[Abstract][Full Text]
Edwards-Bennett, S. M., Jacks, L. M., Moskowitz, C. H., Wu, E. J., Zhang, Z., Noy, A., Portlock, C. S., Straus, D. J., Zelenetz, A. D., Yahalom, J.
(2009). Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol
0: mdp337v1-mdp337
[Abstract][Full Text]
Schwartz, C. L., Constine, L. S., Villaluna, D., London, W. B., Hutchison, R. E., Sposto, R., Lipshultz, S. E., Turner, C. S., deAlarcon, P. A., Chauvenet, A.
(2009). A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood
114: 2051-2059
[Abstract][Full Text]
Owadally, W. S., Sydes, M. R., Radford, J. A., Hancock, B. W., Cullen, M. H., Stenning, S. P., Johnson, P. W. M.
(2009). Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol
0: mdp331v1-mdp331
[Abstract][Full Text]
Samol, J., Susan, K. J
(2009). Unexpected finding on staging bone marrow aspirate for Hodgkin's lymphoma. BMJ Case Reports
2009: bcr1220081298-bcr1220081298
[Full Text]
Brusamolino, E., Bacigalupo, A., Barosi, G., Biti, G., Gobbi, P. G., Levis, A., Marchetti, M., Santoro, A., Zinzani, P. L., Tura, S.
(2009). Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. haematol
94: 550-565
[Abstract][Full Text]
Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M., Gobbi, P. G.
(2009). ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. JCO
27: 805-811
[Abstract][Full Text]
Lister, T. A.
(2008). Treatment of Stage IIIa Hodgkin's Disease: Long Follow-Up Perspective. JCO
26: 5144-5146
[Full Text]
Doussis-Anagnostopoulou, I. A., Vassilakopoulos, T. P., Thymara, I., Korkolopoulou, P., Angelopoulou, M. K., Siakantaris, M. P., Kokoris, S. I., Dimitriadou, E. M., Kalpadakis, C., Matzouranis, M., Kaklamanis, L., Panayiotidis, P., Kyrtsonis, M.-C., Androulaki, A., Patsouris, E., Kittas, C., Pangalis, G. A.
(2008). Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. Clin. Cancer Res.
14: 1759-1766
[Abstract][Full Text]
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I., Levis, A.
(2007). Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. JCO
25: 3746-3752
[Abstract][Full Text]
Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Muller, R.-P., Muller-Hermelink, H. K., Duhmke, E., Diehl, V.
(2007). Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. JCO
25: 3495-3502
[Abstract][Full Text]
van der Kaaij, M. A.E., Heutte, N., Le Stang, N., Raemaekers, J. M.M., Simons, A. H.M., Carde, P., Noordijk, E. M., Ferme, C., Thomas, J., Eghbali, H., Kluin-Nelemans, H. C., Henry-Amar, M.
(2007). Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. JCO
25: 2825-2832
[Abstract][Full Text]
Drakos, E., Thomaides, A., Medeiros, L. J., Li, J., Leventaki, V., Konopleva, M., Andreeff, M., Rassidakis, G. Z.
(2007). Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma. Clin. Cancer Res.
13: 3380-3387
[Abstract][Full Text]
Sieniawski, M., Franklin, J., Nogova, L., Glossmann, J.-P., Schober, T., Nisters-Backes, H., Diehl, V., Josting, A.
(2007). Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-Stage Favorable Hodgkin's Lymphoma. JCO
25: 2000-2005
[Abstract][Full Text]
Boleti, E., Mead, G.
(2007). ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol
18: 376-380
[Abstract][Full Text]
Byrne, B. J., Gockerman, J. P.
(2007). Salvage Therapy in Hodgkin's Lymphoma. The Oncologist
12: 156-167
[Abstract][Full Text]
Dabaja, B., Cox, J. D., Buchholz, T. A.
(2007). Radiation Therapy Can Still Be Used Safely in Combined Modality Approaches in Patients With Hodgkin's Lymphoma. JCO
25: 3-5
[Full Text]
Horning, S. J.
(2007). Risk, Cure and Complications in Advanced Hodgkin Disease. ASH Education Book
2007: 197-203
[Abstract][Full Text]
Venugopal, P., Gregory, S. A.
(2007). Lymphoproliferative disorders. ASH-SAP
2007: 265-297
[Full Text]
Guadagnolo, B. A., Punglia, R. S., Kuntz, K. M., Mauch, P. M., Ng, A. K.
(2006). Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease. JCO
24: 4116-4122
[Abstract][Full Text]
Sanchez-Aguilera, A., Montalban, C., de la Cueva, P., Sanchez-Verde, L., Morente, M. M., Garcia-Cosio, M., Garcia-Larana, J., Bellas, C., Provencio, M., Romagosa, V., de Sevilla, A. F., Menarguez, J., Sabin, P., Mestre, M. J., Mendez, M., Fresno, M. F., Nicolas, C., Piris, M. A., Garcia, J. F., for the Spanish Hodgkin Lymphoma Study Group,
(2006). Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood
108: 662-668
[Abstract][Full Text]
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., Demetri, G., Desch, C. E., Pizzo, P. A., Schiffer, C. A., Schwartzberg, L., Somerfield, M. R., Somlo, G., Wade, J. C., Wade, J. L., Winn, R. J., Wozniak, A. J., Wolff, A. C.
(2006). 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. JCO
24: 3187-3205
[Abstract][Full Text]
Foltz, L. M., Song, K. W., Connors, J. M.
(2006). Hodgkin's Lymphoma in Adolescents. JCO
24: 2520-2526
[Abstract][Full Text]
Cheson, B. D., Canellos, G. P.
(2006). The cancer and leukemia group B lymphoma committee.. Clin. Cancer Res.
12: 3572s-3575s
[Abstract][Full Text]
Ansell, S. M., Armitage, J. O.
(2006). Management of Hodgkin Lymphoma. Mayo Clin Proc.
81: 419-426
[Abstract][Full Text]
Yahalom, J.
(2006). Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma. JCO
24: 544-548
[Full Text]
Schonfeld, S. J., Gilbert, E. S., Dores, G. M., Lynch, C. F., Hodgson, D. C., Hall, P., Storm, H., Andersen, A., Pukkala, E., Holowaty, E., Kaijser, M., Andersson, M., Joensuu, H., Fossa, S. D., Allan, J. M., Travis, L. B.
(2006). Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients. JNCI J Natl Cancer Inst
98: 215-218
[Abstract][Full Text]
Gobbi, P. G., Levis, A., Chisesi, T., Broglia, C., Vitolo, U., Stelitano, C., Pavone, V., Cavanna, L., Santini, G., Merli, F., Liberati, M., Baldini, L., Deliliers, G. L., Angelucci, E., Bordonaro, R., Federico, M.
(2005). ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. JCO
23: 9198-9207
[Abstract][Full Text]
Johnson, P. W.M., Radford, J. A., Cullen, M. H., Sydes, M. R., Walewski, J., Jack, A. S., MacLennan, K. A., Stenning, S. P., Clawson, S., Smith, P., Ryder, D., Hancock, B. W.
(2005). Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). JCO
23: 9208-9218
[Abstract][Full Text]
Carde, P.
(2005). The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side?. JCO
23: 9058-9062
[Full Text]
Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., Ansell, S. M.
(2005). Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma. JCO
23: 7614-7620
[Abstract][Full Text]
Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C. F., Pee, D., Smith, S. A., Van't Veer, M. B., Joensuu, T., Storm, H., Stovall, M., Boice, J. D. Jr., Gilbert, E., Gail, M. H.
(2005). Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. JNCI J Natl Cancer Inst
97: 1428-1437
[Abstract][Full Text]
Duwe, B. V., Sterman, D. H., Musani, A. I.
(2005). Tumors of the Mediastinum. Chest
128: 2893-2909
[Abstract][Full Text]
Connors, J. M.
(2005). State-of-the-Art Therapeutics: Hodgkin's Lymphoma. JCO
23: 6400-6408
[Abstract][Full Text]
Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K., Diehl, V.
(2005). Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group. JCO
23: 5052-5060
[Abstract][Full Text]
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., Burns, B. F., Winter, J. N., Horning, S. J., Dar, A. R., Djurfeldt, M. S., Ding, K., Shepherd, L. E.
(2005). Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. JCO
23: 4634-4642
[Abstract][Full Text]
Josting, A., Nogova, L., Franklin, J., Glossmann, J.-P., Eich, H. T., Sieber, M., Schober, T., Boettcher, H.-D., Schulz, U., Muller, R.-P., Diehl, V., Engert, A.
(2005). Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. JCO
23: 1522-1529
[Abstract][Full Text]
Ballova, V., Ruffer, J.-U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H. K., Duhmke, E., Worst, P., Wilhelmy, M., Naumann, R., Hentrich, M., Eich, H. T., Josting, A., Loffler, M., Diehl, V., Engert, A.
(2005). A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol
16: 124-131
[Abstract][Full Text]
Connors, J. M.
(2005). Evolving Approaches to Primary Treatment of Hodgkin Lymphoma. ASH Education Book
2005: 239-244
[Abstract][Full Text]
Tobinai, K., Hotta, T.
(2004). Clinical Trials for Malignant Lymphoma in Japan. Jpn J Clin Oncol
34: 369-378
[Abstract][Full Text]
Canellos, G. P., Duggan, D., Johnson, J., Niedzwiecki, D.
(2004). How Important Is Bleomycin in the Adriamycin + Bleomycin + Vinblastine + Dacarbazine Regimen?. JCO
22: 1532-1533
[Full Text]
Ng, A. K., Li, S., Neuberg, D., Silver, B., Stevenson, M. A., Fisher, D. C., Mauch, P. M.
(2004). Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. Ann Oncol
15: 270-275
[Abstract][Full Text]
Sieber, M., Tesch, H., Pfistner, B., Rueffer, U., Paulus, U., Munker, R., Hermann, R., Doelken, G., Koch, P., Oertel, J., Roller, S., Worst, P., Bischof, H., Glunz, A., Greil, R., von Kalle, K., Schalk, K. P., Hasenclever, D., Brosteanu, O., Duehmke, E., Georgii, A., Engert, A., Loeffler, M., Diehl, V.
(2004). Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol
15: 276-282
[Abstract][Full Text]
Laskar, S., Gupta, T., Vimal, S., Muckaden, M.A., Saikia, T.K., Pai, S.K., Naresh, K.N., Dinshaw, K.A.
(2004). Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?. JCO
22: 62-68
[Abstract][Full Text]
Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J., Myers, R., Ding, K., Paul, N., Shepherd, L., Iglesias, J., Meyer, R., Crump, M.
(2003). Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol
14: 1762-1767
[Abstract][Full Text]
Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Duhmke, E., Willich, N., Muller, R.-P., Schmidt, B. F., Renner, H., Muller-Hermelink, H. K., Pfistner, B., Wolf, J., Hasenclever, D., Loffler, M., Diehl, V.
(2003). Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. JCO
21: 3601-3608
[Abstract][Full Text]
Josting, A., Wiedenmann, S., Franklin, J., May, M., Sieber, M., Wolf, J., Engert, A., Diehl, V.
(2003). Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin's Disease: A Report From the German Hodgkin's Lymphoma Study Group. JCO
21: 3440-3446
[Abstract][Full Text]
Connors, J. M.
(2003). Hodgkin's Lymphoma: The Hazards of Success. JCO
21: 3388-3390
[Full Text]
Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., Van't Veer, M. B., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, J. D. Jr, Gilbert, E.
(2003). Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA
290: 465-475
[Abstract][Full Text]
Longo, D. L.
(2003). Radiation Therapy in the Treatment of Hodgkin's Disease--Do You See What I See?. JNCI J Natl Cancer Inst
95: 928-929
[Full Text]
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G.
(2003). Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood
102: 53-59
[Abstract][Full Text]
Federico, M., Bellei, M., Brice, P., Brugiatelli, M., Nagler, A., Gisselbrecht, C., Moretti, L., Colombat, P., Luminari, S., Fabbiano, F., Di Renzo, N., Goldstone, A., Carella, A. M.
(2003). High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy. JCO
21: 2320-2325
[Abstract][Full Text]
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.-K., Duhmke, E., Loeffler, M., the German Hodgkin's Lymphoma Study Group,
(2003). Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. NEJM
348: 2386-2395
[Abstract][Full Text]
Aleman, B. M.P., Raemaekers, J. M.M., Tirelli, U., Bortolus, R., van 't Veer, M. B., Lybeert, M. L.M., Keuning, J. J., Carde, P., Girinsky, T., van der Maazen, R. W.M., Tomsic, R., Vovk, M., van Hoof, A., Demeestere, G., Lugtenburg, P. J., Thomas, J., Schroyens, W., De Boeck, K., Baars, J. W., Kluin-Nelemans, J. C., Carrie, C., Aoudjhane, M., Bron, D., Eghbali, H., Smit, W. G.J.M., Meerwaldt, J. H., Hagenbeek, A., Pinna, A., Henry-Amar, M., the European Organization for Research and Treatme,
(2003). Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. NEJM
348: 2396-2406
[Abstract][Full Text]
Herling, M., Rassidakis, G. Z., Medeiros, L. J., Vassilakopoulos, T. P., Kliche, K.-O., Nadali, G., Viviani, S., Bonfante, V., Giardini, R., Chilosi, M., Kittas, C., Gianni, A. M., Bonadonna, G., Pizzolo, G., Pangalis, G. A., Cabanillas, F., Sarris, A. H.
(2003). Expression of Epstein-Barr Virus Latent Membrane Protein-1 in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Lymphoma: Associations with Presenting Features, Serum Interleukin 10 Levels, and Clinical Outcome. Clin. Cancer Res.
9: 2114-2120
[Abstract][Full Text]
Sieber, M., Bredenfeld, H., Josting, A., Reineke, T., Rueffer, U., Koch, T., Naumann, R., Boissevain, F., Koch, P., Worst, P., Soekler, M., Eich, H., Muller-Hermelink, H.K., Franklin, J., Paulus, U., Wolf, J., Engert, A., Diehl, V.
(2003). 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin's Lymphoma: Results of a Pilot Study of the German Hodgkin's Lymphoma Study Group. JCO
21: 1734-1739
[Abstract][Full Text]
Provencio, M., Corbacho, C., Salas, C., Millan, I., Espana, P., Bonilla, F., Ramon Cajal, S.
(2003). The Topoisomerase II{alpha} Expression Correlates with Survival in Patients with Advanced Hodgkin's Lymphoma. Clin. Cancer Res.
9: 1406-1411
[Abstract][Full Text]
Diehl, V.
(2003). Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough!. JCO
21: 583-585
[Full Text]
Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I., Connors, J. M., Canellos, G. P., Peterson, B. A.
(2003). Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial. JCO
21: 607-614
[Abstract][Full Text]
Canellos, G. P., Gollub, J., Neuberg, D., Mauch, P., Shulman, L. N.
(2003). Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol
14: 268-272
[Abstract][Full Text]
Rassidakis, G. Z., Medeiros, L. J., Vassilakopoulos, T. P., Viviani, S., Bonfante, V., Nadali, G., Herling, M., Angelopoulou, M. K., Giardini, R., Chilosi, M., Kittas, C., McDonnell, T. J., Bonadonna, G., Gianni, A. M., Pizzolo, G., Pangalis, G. A., Cabanillas, F., Sarris, A. H.
(2002). BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood
100: 3935-3941
[Abstract][Full Text]
Radman, I., Basic, N., Labar, B., Kovacevic, J., Aurer, I., Bogdanic, V., Zupancic-Salek, S., Nemet, D., Jakic-Razumovic, J., Mrsic, M., Santek, F., Grgic-Markulin, L., Boban, D.
(2002). Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol
13: 1650-1655
[Abstract][Full Text]
Canellos, G. P., Niedzwiecki, D.
(2002). Long-Term Follow-up of Hodgkin's Disease Trial. NEJM
346: 1417-1418
[Full Text]
Rassidakis, G. Z., Medeiros, L. J., Viviani, S., Bonfante, V., Nadali, G.-P., Vassilakopoulos, T. P., Mesina, O., Herling, M., Angelopoulou, M. K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M. A., Romaguera, J., Bonadonna, G., Gianni, A. M., Pizzolo, G., Pangalis, G. A., Cabanillas, F., Sarris, A. H.
(2002). CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. JCO
20: 1278-1287
[Abstract][Full Text]
Weekes, C. D., Vose, J. M., Lynch, J. C., Weisenburger, D. D., Bierman, P. J., Greiner, T., Bociek, G., Enke, C., Bast, M., Chan, W. C., Armitage, J. O.
(2002). Hodgkin's Disease in the Elderly: Improved Treatment Outcome With a Doxorubicin-Containing Regimen. JCO
20: 1087-1093
[Abstract][Full Text]
Travis, L. B., Gospodarowicz, M., Curtis, R. E., Aileen Clarke, E., Andersson, M., Glimelius, B., Joensuu, T., Lynch, C. F., van Leeuwen, F. E., Holowaty, E., Storm, H., Glimelius, I., Pukkala, E., Stovall, M., Fraumeni, J. F. Jr., Boice, J. D. Jr., Gilbert, E.
(2002). Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease. JNCI J Natl Cancer Inst
94: 182-192
[Abstract][Full Text]
Canellos, G. P.
(2002). New Treatments for Advanced Hodgkin's Disease: An Uphill Fight Beginning Close to the Top. JCO
20: 607-609
[Full Text]
Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., Rosenberg, S. A.
(2002). Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial. JCO
20: 630-637
[Abstract][Full Text]
Rassidakis, G. Z., Medeiros, L. J., McDonnell, T. J., Viviani, S., Bonfante, V., Nadali, G., Vassilakopoulos, T. P., Giardini, R., Chilosi, M., Kittas, C., Gianni, A. M., Bonadonna, G., Pizzolo, G., Pangalis, G. A., Cabanillas, F., Sarris, A. H.
(2002). BAX Expression in Hodgkin and Reed-Sternberg Cells of Hodgkin's Disease: Correlation with Clinical Outcome. Clin. Cancer Res.
8: 488-493
[Abstract][Full Text]
Ferme, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A., Reman, O., Voillat, L., Jaubert, J., Lederlin, P., Colin, P., Berger, F., Salles, G.
(2002). Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. JCO
20: 467-475
[Abstract][Full Text]
Sieber, M., Tesch, H., Pfistner, B., Rueffer, U., Lathan, B., Brosteanu, O., Paulus, U., Koch, T., Pfreundschuh, M., Loeffler, M., Engert, A., Josting, A., Wolf, J., Hasenclever, D., Franklin, J., Duehmke, E., Georgii, A., Schalk, K.-P., Kirchner, H., Doelken, G., Munker, R., Koch, P., Herrmann, R., Greil, R., Anselmo, A. P., Diehl, V.
(2002). Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5. JCO
20: 476-484
[Abstract][Full Text]
Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M. K., Heinz, J., Rudolph, C., Diehl, V., Engert, A.
(2002). New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study Group. JCO
20: 221-230
[Abstract][Full Text]
Press, O. W., LeBlanc, M., Lichter, A. S., Grogan, T. M., Unger, J. M., Wasserman, T. H., Gaynor, E. R., Peterson, B. A., Miller, T. P., Fisher, R. I.
(2001). Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin's Disease. JCO
19: 4238-4244
[Abstract][Full Text]
Sleijfer, S.
(2001). Bleomycin-Induced Pneumonitis. Chest
120: 617-624
[Abstract][Full Text]
Connors, J. M., Noordijk, E. M., Horning, S. J.
(2001). Hodgkin's Lymphoma: Basing the Treatment on the Evidence. ASH Education Book
2001: 178-193
[Abstract][Full Text]
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro,
(2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO
18: 3558-3585
[Full Text]
Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V., Engert, A.
(2000). Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood
96: 1280-1286
[Abstract][Full Text]
Baynes, R. D., Hamm, C., Dansey, R., Klein, J., Cassells, L., Karanes, C., Abella, E., Peters, W. P.
(2000). Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting. Clin. Chem.
46: 1239-1251
[Abstract][Full Text]
Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., Fiedler, F., Parra, H. S., Benoehr, C., Pacini, M., Bonadonna, G., Diehl, V.
(2000). Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study. JCO
18: 2615-2619
[Abstract][Full Text]
Horning, S. J., Williams, J., Bartlett, N. L., Bennett, J. M., Hoppe, R. T., Neuberg, D., Cassileth, P.
(2000). Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492. JCO
18: 972-972
[Abstract][Full Text]
Takenaka, T., Mikuni, C., Miura, A., Sasaki, T., Suzuki, H., Hotta, T., Hirano, M., Fukuhara, S., Sugiyama, H., Nasu, K., Dohi, H., Kozuru, M., Tomonaga, M., Tajima, K., Niimi, M., Fukuda, H., Mukai, K.
(2000). Alternating Combination Chemotherapy C-MOPP (Cyclophosphamide, Vincristine, Procarbazine, Prednisone) and ABVd (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) in Clinical Stage II-IV Hodgkin's Disease: a Multicenter Phase II Study (JCOG 8905). Jpn J Clin Oncol
30: 146-152
[Abstract][Full Text]
Josting, A., Reiser, M., Rueffer, U., Salzberger, B., Diehl, V., Engert, A.
(2000). Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?. JCO
18: 332-332
[Abstract][Full Text]
Linch, D. C., Gosden, R. G., Tulandi, T., Tan, S.-L., Hancock, S. L.
(2000). Hodgkin's Lymphoma: Choice of Therapy and Late Complications. ASH Education Book
2000: 205-221
[Abstract][Full Text]
Ng, A. K., Weeks, J. C., Mauch, P. M., Kuntz, K. M.
(1999). Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease. JCO
17: 3577-3585
[Abstract][Full Text]
Groopman, J. E., Itri, L. M.
(1999). Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. JNCI J Natl Cancer Inst
91: 1616-1634
[Abstract][Full Text]
Sweetenham, J. W., Carella, A. M., Taghipour, G., Cunningham, D., Marcus, R., Volpe, A. D., Linch, D. C., Schmitz, N., Goldstone, A. H.
(1999). High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation. JCO
17: 3101-3109
[Abstract][Full Text]
Rodriguez, J., Rodriguez, M.A., Fayad, L., McLaughlin, P., Swan, F., Sarris, A., Romaguera, J., Andersson, B., Cabanillas, F., Hagemeister, F.B.
(1999). ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease. Blood
93: 3632-3636
[Abstract][Full Text]
Imashuku, S., Hibi, S., Ohara, T., Iwai, A., Sako, M., Kato, M., Arakawa, H., Sotomatsu, M., Kataoka, S., Asami, K., Hasegawa, D., Kosaka, Y., Sano, K., Igarashi, N., Maruhashi, K., Ichimi, R., Kawasaki, H., Maeda, N., Tanizawa, A., Arai, K., Abe, T., Hisakawa, H., Miyashita, H., Henter, J.-I.
(1999). Effective Control of Epstein-Barr Virus-Related Hemophagocytic Lymphohistiocytosis With Immunochemotherapy. Blood
93: 1869-1874
[Abstract][Full Text]
Lazarus, B. H. M., Rowlings, P. A., Zhang, M.-J., Vose, J. M., Armitage, J. O., Bierman, P. J., Gajewski, J. L., Gale, R. P., Keating, A., Klein, J. P., Miller, C. B., Phillips, G. L., Reece, D. E., Sobocinski, K. A., van Besien, K., Horowitz, M. M.
(1999). Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry. JCO
17: 534-534
[Abstract][Full Text]
Andrieu, J. M., Yilmaz, U., Colonna, P., Loeffler, M., Brosteanu, O., Hasenclever, D.
(1999). MOPP Versus ABVD and Low-Dose Versus High-Dose Irradiation in Hodgkin's Disease at Intermediate and Advanced Stages: Analysis of a Meta-Analysis by Clinicians. JCO
17: 730-730
[Full Text]
Aisenberg, A. C.
(1999). Problems in Hodgkin's Disease Management. Blood
93: 761-779
[Full Text]
Andre, M., Henry-Amar, M., Pico, J.-L., Brice, P., Blaise, D., Kuentz, M., Coiffier, B., Colombat, P., Cahn, J.-Y., Attal, M., Fleury, J., Milpied, N., Nedellec, G., Biron, P., Tilly, H., Jouet, J.-P., Gisselbrecht, C.
(1999). Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. JCO
17: 222-222
[Abstract][Full Text]
Ng, A. K., Weeks, J. C., Mauch, P. M., Kuntz, K. M.
(1999). Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis. JCO
17: 241-241
[Abstract][Full Text]
Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U., Loeffler, M.
(1998). Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group. Blood
92: 4560-4567
[Abstract][Full Text]
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Bjorkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., Eghbali, H., Ferm, C., Fisher, R. I., Glick, J. H., Glimelius, B., Gobbi, P. G., Holte, H., Horning, S. J., Lister, T. A., Longo, D. L., Mandelli, F., Polliack, A., Proctor, S. J., Specht, L., Sweetenham, J. W., Hudson, G. V., The International Prognostic Factors Project on Ad,
(1998). A Prognostic Score for Advanced Hodgkin's Disease. NEJM
339: 1506-1514
[Abstract][Full Text]
Gobbi, P. G., Pieresca, C., Ghirardelli, M. L., DiRenzo, N., Federico, M., Merli, F., Iannitto, E., Pitini, V., Grignani, G., Donelli, A., Carotenuto, M., Silingardi, V., Ascari, E., The Gruppo Italiano per lo Studio dei Linfomi,
(1998). Long-Term Results From MOPPEBVCAD Chemotherapy With Optional Limited Radiotherapy in Advanced Hodgkin's Disease. Blood
91: 2704-2712
[Abstract][Full Text]
Previous
